{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.51","value":"11.05"}]}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.03","value":"0.48"}]}],"title":"Change at Evaluation Period"}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"description":"The Hb change from baseline was calculated on a per-participant basis using an individual's average for both the baseline and evaluation periods and taking the difference. The baseline period was defined as the time between the day of first study dose and the previous 35 days. The evaluation period was defined as the period between Week 17 and Week 21, inclusive.","dispersionType":"Standard Deviation","groups":[{"description":"Mircera was administered subcutaneously once every 4 weeks.","id":"OG000","title":"Mircera"}],"paramType":"MEAN","populationDescription":"ITT population included all participants enrolled in the study. Number analyzed is the number of participants with Hb concentration assessment at specified time points.","reportingStatus":"POSTED","timeFrame":"Baseline up to Week 21","title":"Change in Hemoglobin (Hb) Concentration Between the Baseline and the Evaluation Period for Each Patient","type":"PRIMARY","unitOfMeasure":"grams/deciliter (g/dL)"}